Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
82 hedge funds and large institutions have $314M invested in Avadel Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 8 closing their positions.
928% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $1.6M
43% more capital invested
Capital invested by funds: $219M → $314M (+$95.1M)
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 80 → 82 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.84% less ownership
Funds ownership: 55.55% → 54.7% (-0.84%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$11.8M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.15M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$2.94M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.59M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$833K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$16.5M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.42M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$1.39M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$1.36M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$1.3M |
AVDL Hedge Fund Activity: Q3 2021 in Review
82 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2021, worth a combined $314M — up 43% from $219M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AVDL positions and 8 closed out — a net gain of 2 holders — while 28 added to existing stakes and 21 trimmed.
The largest buyer was Woodline Partners, adding an estimated $11.8M. The largest seller was Avoro Capital Advisors, cutting an estimated $16.5M.
- 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2021, up from 80 in Q2 2021.
- Funds reported $314M of Avadel Pharmaceuticals stock for Q3 2021, up 43% quarter-over-quarter.
- 10 funds opened new Avadel Pharmaceuticals positions in Q3 2021 and 8 closed out, a net change of +2 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2021 was Woodline Partners, an estimated $11.8M added.
- The largest Avadel Pharmaceuticals seller in Q3 2021 was Avoro Capital Advisors, an estimated $16.5M sold.
Based on aggregated 13F filings for Q3 2021.